Cim Investment Management Inc Ligand Pharmaceuticals Inc Transaction History

Cim Investment Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 17, 2022	SELL	$94.99 - $151.56 $136,310 - $217,488	-1,435 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$127.69 - $165.85 $183,235 - $237,994	1,435 New	1,435 $222,000
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $220,521 - $311,893	-2,155 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$113.03 - $155.64 $243,579 - $335,404	2,155 New	2,155 $283,000
Q1 2021 May 20, 2021	SELL	$99.52 - $215.83 $243,425 - $527,920	-2,446 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $3,224 - $4,561	36 Added 1.49%	2,446 $233,000
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $164,554 - $297,996	2,410 New	2,410 $270,000
Q1 2020 May 22, 2020	SELL	$63.37 - $107.88 $126,740 - $215,760	-2,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $151,711 - $177,768	-1,565 Reduced 43.9%	2,000 $209,000
Q2 2019 Aug 08, 2019	SELL	$107.38 - $129.34 $7,516 - $9,053	-70 Reduced 1.93%	3,565 $407,000
Q1 2019 May 13, 2019	BUY	$105.93 - $142.47 $159,742 - $214,844	1,508 Added 70.9%	3,635 $457,000
Q4 2018 Feb 05, 2019	BUY	$128.36 - $272.13 $273,021 - $578,820	2,127 New	2,127 $289,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.03B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Cim Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cim Investment Management Inc with notifications on news.